Drug Details

General Information of the Drug (ID: DR3561)
Name
LY294002
Synonyms
154447-36-6; LY294002; LY 294002; LY-294002; 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 2-morpholino-8-phenyl-4H-chromen-4-one; 2-morpholin-4-yl-8-phenyl-4H-chromen-4-one; UNII-31M2U1DVID; 2-(morpholin-4-yl)-8-phenyl-4H-chromen-4-one; NSC 697286; 31M2U1DVID; 2-MORPHOLIN-4-YL-7-PHENYL-4H-CHROMEN-4-ONE; CHEMBL98350; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-; CHEBI:65329; LY2; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl; LY-294,002; 2-Morpholin-4-yl-8-phenyl-chromen-4-one; BMK1-D5; Lys 294002; 4azt; 2-morpholino-8-phenyl-chromen-4-one; 15447-36-6; SF 1101; Kinome_3543; PubChem16766; Tocris-1130; 1yi3; BiomolKI_000029; 2-(morpholin-4-yl)-8-phenylchromen-4-one; Lopac-L-9908; 8-Phenyl-2-(morpholin-4-yl)-chromen-4-one; BiomolKI2_000037; cc-58; CBiol_002046; Lopac0_000710; SCHEMBL94377; BSPBio_001223; KBioGR_000563; KBioSS_000563; MLS006010131; 2-Morpholino-8-phenylchromone; 2-(4-morpholino)-8-phenyl-4H-1-benzopyran-4-one; GTPL6004; ZINC6014; DTXSID6042650; BCBcMAP01_000117; BDBM12915; KBio2_000563; KBio2_003131; KBio2_005699; KBio3_001005; KBio3_001006; EX-A073; SYN1108; BCPP000177; Bio1_000332; Bio1_000821; Bio1_001310; Bio2_000442; Bio2_000922; HMS1362M05; HMS1792M05; HMS1990M05; HMS3229G17; HMS3403M05; HMS3649E04; HMS3654M21; AMY40921; BCP00195; HSCI1_000206; NSC697286; NSC755769; s1105; AKOS017344742; BCP9000880; CCG-100633; CS-0150; DB02656; NSC-697286; NSC-755769; QC-7260; SB10965; SDCCGSBI-0050688.P003; SF-1101; IDI1_002197; NCGC00015622-01; NCGC00015622-02; NCGC00015622-03; NCGC00015622-04; NCGC00015622-05; NCGC00015622-06; NCGC00015622-07; NCGC00015622-23; NCGC00025020-01; NCGC00025020-02; NCGC00025020-03; NCGC00025020-04; NCGC00179253-01; AC-30295; AK162301; AS-16252; HY-10108; NCI60_034712; SMR002530642; AB0033714; LY-924002; FT-0660382; M2410; SW217688-2; X7411; EC-000.2341; 2-Morpholino-8-phenyl-4-oxo-4H-1-benzopyran; C15195; K00235; S-7706; J-510126; Q4042503; SR-01000076245-7; 4H-1-Benzopyran-4-one,2-(4-morpholinyl)-8-phenyl-; BRD-K27305650-001-05-9; InSolution LY 294002 - CAS 154447-36-6; LY-294,002 hydrochloride, solid, >=98% (HPLC); LY 294002 - CAS 154447-36-6; 4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl- (9CI); H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl- (9CI); LY 294002; 2-(4-Morpholino)-8-phenyl-4H-1-benzopyran-4-one
    Click to Show/Hide
Molecular Type
Small molecule
Disease Adrenocortical carcinoma [ICD-11: 2D11] Phase 1 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C19H17NO3
PubChem CID
3973
Canonical SMILES
C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
InChI
1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2
InChIKey
CZQHHVNHHHRRDU-UHFFFAOYSA-N
CAS Number
CAS 154447-36-6
ChEBI ID
CHEBI:65329
TTD Drug ID
D09SFV
DrugBank ID
DB02656
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Arsenic trioxide      Realgar and orpiment     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Phosphorylation AKT1  Molecule Info 
Pathway MAP
Down-regulation Expression Gli1  Molecule Info 
Pathway MAP
                    In-vitro Model HCT 116 CVCL_0291 Colon carcinoma Homo sapiens
HT29 CVCL_A8EZ Colorectal adenocarcinoma Mus musculus
                    Experimental
                    Result(s)		 Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002 synergistically inhibite colon carcinoma cell growth.
Target and Pathway
Target(s) PI3-kinase gamma (PIK3CG)  Molecule Info  [3]
KEGG Pathway Inositol phosphate metabolism Click to Show/Hide
2 ErbB signaling pathway
3 Ras signaling pathway
4 Rap1 signaling pathway
5 cGMP-PKG signaling pathway
6 cAMP signaling pathway
7 Chemokine signaling pathway
8 HIF-1 signaling pathway
9 FoxO signaling pathway
10 Phosphatidylinositol signaling system
11 Sphingolipid signaling pathway
12 mTOR signaling pathway
13 PI3K-Akt signaling pathway
14 AMPK signaling pathway
15 Apoptosis
16 Adrenergic signaling in cardiomyocytes
17 VEGF signaling pathway
18 Osteoclast differentiation
19 Focal adhesion
20 Signaling pathways regulating pluripotency of stem cells
21 Platelet activation
22 Toll-like receptor signaling pathway
23 Jak-STAT signaling pathway
24 Natural killer cell mediated cytotoxicity
25 T cell receptor signaling pathway
26 B cell receptor signaling pathway
27 Fc epsilon RI signaling pathway
28 Fc gamma R-mediated phagocytosis
29 TNF signaling pathway
30 Leukocyte transendothelial migration
31 Neurotrophin signaling pathway
32 Cholinergic synapse
33 Inflammatory mediator regulation of TRP channels
34 Regulation of actin cytoskeleton
35 Insulin signaling pathway
36 Progesterone-mediated oocyte maturation
37 Estrogen signaling pathway
38 Prolactin signaling pathway
39 Thyroid hormone signaling pathway
40 Oxytocin signaling pathway
41 Regulation of lipolysis in adipocytes
42 Type II diabetes mellitus
43 Non-alcoholic fatty liver disease (NAFLD)
44 Aldosterone-regulated sodium reabsorption
45 Carbohydrate digestion and absorption
46 Bacterial invasion of epithelial cells
47 Chagas disease (American trypanosomiasis)
48 Toxoplasmosis
49 Amoebiasis
50 Hepatitis C
51 Hepatitis B
52 Measles
53 Influenza A
54 HTLV-I infection
55 Epstein-Barr virus infection
56 Pathways in cancer
57 Viral carcinogenesis
58 Proteoglycans in cancer
59 MicroRNAs in cancer
60 Colorectal cancer
61 Renal cell carcinoma
62 Pancreatic cancer
63 Endometrial cancer
64 Glioma
65 Prostate cancer
66 Melanoma
67 Chronic myeloid leukemia
68 Acute myeloid leukemia
69 Small cell lung cancer
70 Non-small cell lung cancer
71 Central carbon metabolism in cancer
72 Choline metabolism in cancer
Pathwhiz Pathway Inositol Metabolism Click to Show/Hide
2 Phosphatidylinositol Phosphate Metabolism
3 Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
4 Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
5 Fc Epsilon Receptor I Signaling in Mast Cells
Reactome PI3K Cascade Click to Show/Hide
2 GPVI-mediated activation cascade
3 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
4 PI3K events in ERBB4 signaling
5 PIP3 activates AKT signaling
6 GAB1 signalosome
7 PI3K events in ERBB2 signaling
8 PI3K/AKT activation
9 Role of phospholipids in phagocytosis
10 Tie2 Signaling
11 Constitutive Signaling by Aberrant PI3K in Cancer
12 DAP12 signaling
13 Role of LAT2/NTAL/LAB on calcium mobilization
14 Nephrin interactions
15 Costimulation by the CD28 family
16 CD28 dependent PI3K/Akt signaling
17 G beta:gamma signalling through PI3Kgamma
18 G alpha (q) signalling events
19 G alpha (12/13) signalling events
20 VEGFA-VEGFR2 Pathway
21 Interleukin-3, 5 and GM-CSF signaling
22 Constitutive Signaling by EGFRvIII
23 PI-3K cascade:FGFR1
24 PI-3K cascade:FGFR2
25 PI-3K cascade:FGFR3
26 PI-3K cascade:FGFR4
27 Interleukin receptor SHC signaling
28 Regulation of signaling by CBL
WikiPathways Toll-like receptor signaling pathway Click to Show/Hide
2 Serotonin HTR1 Group and FOS Pathway
3 DNA Damage Response (only ATM dependent)
4 G13 Signaling Pathway
5 Regulation of Actin Cytoskeleton
6 Insulin Signaling
7 IL-4 Signaling Pathway
8 Copper homeostasis
9 Signaling of Hepatocyte Growth Factor Receptor
10 Transcriptional activation by NRF2
11 IL1 and megakaryotyces in obesity
12 Signaling by ERBB4
13 Signaling by ERBB2
14 Fc epsilon receptor (FCERI) signaling
15 PI Metabolism
16 Interleukin-2 signaling
17 Fcgamma receptor (FCGR) dependent phagocytosis
18 Signaling by SCF-KIT
19 DAP12 interactions
20 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
21 Gastrin-CREB signalling pathway via PKC and MAPK
22 PIP3 activates AKT signaling
23 Integrated Pancreatic Cancer Pathway
24 Prostate Cancer
25 Signaling Pathways in Glioblastoma
26 TSLP Signaling Pathway
27 Regulation of Microtubule Cytoskeleton
28 TSH signaling pathway
29 SREBP signalling
30 TCR signaling
31 Signaling by PDGF
32 Signaling by Insulin receptor
33 Signaling by FGFR
34 Signaling by EGFR
35 NGF signalling via TRKA from the plasma membrane
36 Nephrin interactions
37 Interleukin-3, 5 and GM-CSF signaling
38 GPVI-mediated activation cascade
39 GPCR downstream signaling
40 Costimulation by the CD28 family
41 Cell surface interactions at the vascular wall
42 MicroRNAs in cardiomyocyte hypertrophy
43 Angiogenesis
44 Regulation of toll-like receptor signaling pathway
45 AMPK Signaling
References
Reference 1 ClinicalTrials.gov (NCT02337309) SF1126 for Patients With Relapsed or Refractory Neuroblastoma. U.S. National Institutes of Health.
Reference 2 Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002. Onco Targets Ther. 2015 Apr 17;8:877-83.
Reference 3 Clinical pipeline report, company report or official report of Genentech (2009).
 Download Picture         KEGG Link      
 Download Picture         KEGG Link